A Phase 1a Open-Label, Dose-Escalation Study of the Safety and Pharmacokinetics of OMP-313M32 Administered as a Single Agent to Subjects With Locally Advanced or Metastatic Solid Tumors
Administered By
Awarded By
Contributors
- Mettu, Niharika Bansal Principal Investigator
Start/End
- October 23, 2017 - March 31, 2020